ISLMF (InSilico Medicine Cayman TopCo) Interest Expense: $-0.21 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISLMF InSilico Medicine Cayman TopCo ISLMF
13 GF Score
Price $6.11
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo Interest Expense?

InSilico Medicine Cayman TopCo ISLMF -1.77% 13 Interest Expense is $-0.21 Mil as of Dec. 2025. GuruFocus rates ISLMF with a GF Score™ of 13/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. InSilico Medicine Cayman TopCo's interest expense for the three months ended in Dec. 2025 was $ -0.11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.21 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. InSilico Medicine Cayman TopCo's Operating Income for the three months ended in Dec. 2025 was $ -39.26 Mil. InSilico Medicine Cayman TopCo's Interest Expense for the three months ended in Dec. 2025 was $ -0.11 Mil. InSilico Medicine Cayman TopCo did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InSilico Medicine Cayman TopCo  (OTCPK:ISLMF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InSilico Medicine Cayman TopCo's Interest Expense for the three months ended in Dec. 2025 was $-0.11 Mil. Its Operating Income for the three months ended in Dec. 2025 was $-39.26 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was $4.06 Mil.

InSilico Medicine Cayman TopCo's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

InSilico Medicine Cayman TopCo did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

InSilico Medicine Cayman TopCo Interest Expense Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo Interest Expense Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.10 -0.09 -0.09 -0.21

InSilico Medicine Cayman TopCo Quarterly Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial 0.00 -0.03 -0.06 -0.10 -0.11
ISLMF
13GF Score
InSilico Medicine Cayman TopCo ISLMF
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.21 Mil mean?
InSilico Medicine Cayman TopCo (ISLMF) has a Interest Expense of $-0.21 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on InSilico Medicine Cayman TopCo and its competitors.
Is InSilico Medicine Cayman TopCo's Interest Expense too high?
InSilico Medicine Cayman TopCo's current Interest Expense is $-0.21 Mil. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Interest Expense compare to ?
InSilico Medicine Cayman TopCo's Interest Expense of $-0.21 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Software company?
A good Interest Expense depends on the Software industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current Interest Expense is $-0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current Interest Expense of $-0.21 Mil. The current Interest Expense is $-0.21 Mil. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current Interest Expense is $-0.21 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Comparable Companies
Other Exchanges 03696:Hong KongO15:Germany
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score

Get the complete analysis for ISLMF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.11
Price